We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.75
Bid: 48.00
Ask: 49.50
Change: 3.75 (8.33%)
Spread: 1.50 (3.125%)
Open: 45.00
High: 48.75
Low: 45.60
Prev. Close: 45.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Wed, 24th Feb 2021 11:45

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Proceeding to full clinical valuation for its Covid-19 test to support a CE Mark, with a possible commercial launch of the test for professional use near the end of the first quarter of 2021. Chief Executive Alastair Smith says Avacta is close to fully establishing its supply chain for scalable manufacture of test kits and "making timely progress in instituting a quality management system to support the required ISO13485 accreditation for medical devices". The AffiDX SARS-CoV-2 lateral flow rapid antigen test is, as far as Avacta is aware, "the most sensitive S1 spike lateral flow test available". December 31 cash position GBP28 million, a little higher than market forecasts.

----------

Gooch & Housego PLC - Somerset-based optical components and systems maker - Notes improved levels of demand across industrial laser sector during the first four months of its financial year ending September 2021. This includes, in line with previously reported trends, continuing high levels of demand for fibre optics, hi-reliability fibre couplers as well as its Aerospace & Defence capabilities. Also sees strong growth from Life sciences. Recovering in industrial lasers led by Asian markets, though US and European markets now also showing "encouraging trends" while 5G rollout "has fuelled demand led growth, building on the previously reported recovery in semiconductors". A&D order book robust. Medial diagnostics demonstrating good growth with improves levels of demand for medical laser products, previously hurt by reduced non-Covid-19 procedures in financial 2020. Cash generation robust, net debt further shrinks in first four months of financial year despite payment of final earn out associated with an acquisition. January 31 order book GBP95.0 million, a little higher than the previous year's GBP94.1 million. Streamlining manufacturing sites, with all product lines at Glenrothes, Scotland facility transferred to new UK Precision Optics hub in Ilminster and Glenrothes site now closed. Outsourcing of Acousto Optic products from Ilminster to Asian contract manufacturer "progressing well" and set to complete by financial year end. Begins transferring production from St Asaph, Wales facility to Ilminster Precision Optics hub. Optical systems engineering and design centre to be retained in St Asaph. Target completion of both projects by current financial year end.

----------

Proactis Holdings PLC- Wetherby-based cash management software company - Expects to post a drop in revenue for the six months ended January 31 to GBP23.7 million from GBP24.5 million but with higher adjusted earnings before interest, tax, depreciation, and amortisation of GBP6.2 million versus GBP5.6 million the year before. Explains that its operating margins have improved after it restructures its management team and operating costs base. Says net bank debt at the end of January was GBP39.7 million, up from GBP37.1 million on July 31. Explains that its position has been hurt by a reduction in cash levels from its outsourced sourcing business as a consequence of lower trading volumes due to Covid-19 plus cash flow and upfront costs of the restructure. Expects to post a half-year performance in line with board expectations.

----------

Echo Energy PLC - Latin America focused upstream oil and gas company - Agrees, along with Santa Cruz Sur partners, to capital expenditure for upgrading and debottlenecking the existing liquids pipelines in the Santa Cruz Sur assets, located in onshore Argentina. This will accelerate a return to full oil production and bring remaining volumes, previously shut in the second quarter of 2020, back online. This follows an increase in demand, which resulted in improved pricing and more frequent oil sales. Pipeline upgrades will also grant additional capacity for production enhancement product in the future, which have been identified. Capital expenditure, net to Echo's 70% working interest in Santa Cruz Sur, will be around USD175,000 and will be injected by Echo to replace and upgrade parts of the infrastructure - mostly in the Chorillos, Campo Molino and Cerro Convento fields. Installation is expected to take around 45 days with 10 upgrade projects to be completed, upgrading a total of around 23 kilometres of pipeline and restoring gross daily liquids production to between 480 barrels of oil per day and 600 bopd, or 336bopd to 420 bopd net to Echo. In 2020, total cumulative production net to Echo from Santa Cruz Sur was 720,000 boe. From January

----------

Alba Mineral Resources PLC- mineral exploration and development company with assets in Greenland and the UK - Says it has planned the next phase of regional exploration for the Dolgellau gold exploration project in north Wales. The next phase of work over the field involves stream sediment sampling, which is designed to identify hard-rock gold sources upstream of sampling locations. This will be the first field work to take place over Alba's Gwynfynydd exploration licence area since the licence was warded in November 2020. Chair George Frangeskides, says: "For the first time, we will be expanding our regional exploration programme to cover our recently granted Gwynfynydd exploration licence. We are very optimistic about the prospects for finding new gold deposits in the Dolgellau gold field."

----------

Angling Direct PLC - Norwich, Norfolk-based fishing tackle and equipment retailer - Expects to post a 27% revenue increase for its financial year ended January 31 to GBP67.6 million from GBP53.2 million the year before despite closure of its retail stores and only being able to operate on a "call & collect" basis under lockdown rules. This growth results from online sales, up 40% to GBP35.3 million from GBP25.2 million with. Total store sales, including call & collect, rose 16% to GBP32.3 million from GBP27.9 million with the total number of stores increasing to 38 on January 31 from 34 the prior year and new stores contributed GBP2.2 million in sales. Forecasts pre IFRS-16 Ebitda of at least GP3.8 million for financial 2021 versus a GBP500,000 loss year-on-year. Cash position at January end GBP15.0 million, sharply rising from GBP5.9 million the year before. Not providing guidance for financial 2022 until full extent of Covid-19 disruption is known.

----------

IronRidge Resources Ltd - Australia-based minerals exploration company - Drilling progressing well at the Ewoyaa lithium project in Ghana, with around 4,1000 in 40 reverse circulation holes completed so far. Says visible coarse spodumene mineralisation has been observed in 36 holes to date, with maximum reported pegmatite internals up to 36 metres and approximating true width. Spodumene mineralisation has been observed in most pegmatite targets tested, with good continuity up to 300 metres along strike and down dip. Average pegmatite widths between 10 and 15 metres. So far, three of the seven pegmatite target zones have been drill tested and drilling is ongoing, with assays pending. Chief Executive Vincent Mascolo says: "This drilling programme is a key part of our work towards expanding the resource base on what is widely considered to be an industry-leading asset. We are now evaluating options to fast track the project to production to take advantage of the increasing demand for lithium and its role in the future growth of stored energy initiatives."

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Quilter PLCQ1 Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Whitbread PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.